novo nordisk zepbound

News

Zepbound beats Wegovy for weight loss

Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial. The data is the first head-to-head trial comparing the wildly popular medicines,

· 3d

Novo Nordisk Tumbles as Lilly's Zepbound Shows Greater Weight Loss in Trial

· 3d · on MSN

Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs

1don MSN

Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...

ETFs to Capitalize on the Novo Nordisk-Septerna Deal

Novo Nordisk NVO announced a significant partnership with Septerna SEPN, a U.S.-based biotech company, valued at up to $2.2 billion, to tap the growing obesity treatment market. F ...

MarketBeat on MSN8h

Is It Time to Buy the Dip in Novo Nordisk Stock?

CompanyOverview|NYSE:NVO] Despite a double beat in its quarterly earnings on May 7, Novo Nordisk A/S (NYSE: NVO) stock is ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

News

Zepbound beats Wegovy for weight loss

Trending now